NovartisNovartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care and cost-saving generic pharmaceuticals. Novartis is the only global company with leading positions in these areas. In 2014, the Group achieved net sales of USD 58.0 billion, while R&D throughout the Group amounted to approximately USD 9.9 billion (USD 9.6 billion excluding impairment and amortization charges). Novartis Group companies employ approximately 120,000 full-time-equivalent associates. Novartis products are available in more than 180 countries around the world.

Novartis RSS Channel

Display # 
Title Published Date
Novartis Foundation and partners launch new hypertension program in Ghana 29 October 2015
Novartis broadens immuno-oncology pipeline with acquisition of Admune Therapeutics and licensing agreements with XOMA and Palobiofarma 21 October 2015
Kenya first country to launch 'Novartis Access', expanding affordable treatment options against chronic diseases 15 October 2015
Long-term efficacy of Gilenya® reinforced by new 'no evidence of disease activity' (NEDA-4) analysis in MS patients over seven years 08 October 2015
Novartis launches 'Novartis Access', a portfolio of affordable medicines to treat chronic diseases in lower-income countries 28 September 2015
Patients with aggressive form of melanoma lived for more than two years on average when taking Novartis therapies Tafinlar® + Mekinist® 28 September 2015
Novartis receives EU approval for Farydak®, the first in its class of anticancer agents approved for patients with multiple myeloma 04 September 2015
Novartis announces global partnership with Amgen to develop and commercialize pioneering neuroscience treatments 02 September 2015
Novartis acquires all remaining rights to GSK's Ofatumumab to develop treatments for MS and other autoimmune indications 21 August 2015
Novartis malaria treatment Coartem® 80/480mg receives WHO prequalification, enabling greater access for patients 17 July 2015

Digest World Pharma Newsletter

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]